Previous 10 | Next 10 |
BIO-key International (BKYI) +44% after partnering with Prominic.NET.Ideanomics (IDEX) +33% after increasing stake in e-Tractor company.Kaixin Auto Holdings (KXIN) +32%.DPW Holdings (DPW) +29% after entering new franchise program.CPS Technologies Corporation (CPS...
Shares of Mesoblast (NASDAQ: MESO) were soaring 19.8% higher as of 11:09 a.m. EST on Friday. The big jump came after the company announced an exclusive license and collaboration deal with Novartis (NYSE: NVS) for Mesoblast's lead pipeline candidate remestemcel-L. The initial...
Gainers: Titan Pharmaceuticals (TTNP) +31%, Idera Pharmaceuticals (IDRA) +27%, Mesoblast (MESO) +20%, 22nd Century Group (XXII) +14%, Genfit (GNFT) +13%.Losers: AVROBIO (AVRO) -14%, Stealth BioTherapeutics (MITO) -14%, Kazia Therapeu...
Ayro (AYRO) +28%.Ideanomics (IDEX) +22%.Precision BioSciences (DTIL) +19% after co. enters into a research and license agreement with LLY.Mesoblast Limited (MESO) +17% after entering into an exclusive worldwide license and collaboration agreement with Novartis.Waitr Holdin...
Mesoblast (MESO) surges 17% after entering into an exclusive worldwide license and collaboration agreement with Novartis (NVS) for the development, manufacture and commercialization of Mesoblast’s remestemcel-L, with an initial focus to develop treatment for acute respiratory...
Gainers: [[MESO]] +27.6%. [[FEYE]] +20.4%. [[NGVC]] +15.7%. [[SMTS]] +15.1%. [[CAL]] +8.6%.Losers: [[FTSI]] -18.5%. [[PNNT]] -10%. [[CELP]] -8.4%. [[DUO]] -6.3%. [[ASYS]] -6.3%. For further details see: FEYE, PNNT, MESO and CELP among after-hours movers
Mesoblast (MESO): FQ1 GAAP EPS of -$0.0421 beats by $0.22.Revenue of $1.31M (-92.3% Y/Y) misses by $39.21M.Press Release For further details see: Mesoblast EPS beats by $0.22, misses on revenue
NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational and financial results for the first quarter ended September 30, 2020 (FY2021). Mesoblast has enter...
NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), today announced that it has entered into an exclusive worldwide license and collaboration agreement with Novartis for the development, manufacture and commercialization of Mesoblast’s mesenchymal st...
NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide a corporate update, and report financial and operational highlights for the first quarter ende...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 14:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for MESO on July 23, 2024 12:57PM ET. MESO was trading at $8.29 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 5 - Buy, 2 - H...
NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for...
NEW YORK, July 21, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the confirmatory Phase 3 trial of its allogeneic, immunoselected, and industrially manufactured stromal cell product...